Indeed, co-administration of CX-4945 and erlotinib was able to effectively attenuate the PI3K-AKT-mTOR pathway in both squamous cell carcinoma and non-small cell lung carcinoma (NSCLC) cell lines, leading to reduced activation of AKT and its substrates, thereby inhibiting proliferation and enhancing apoptosis. Here, AKT1 is linked to squamous cell carcinoma.